Tender Details
Description / Scope of Work
The Pakistan Kidney & Liver Institute and Research Center (PKLI) invites sealed bids for the procurement of medicines for Hepatitis B and C treatment across 18 PKLI filter clinics in Punjab for the financial year 2025-2026. This tender is issued under reference PRO-46-2026 and is restricted to pre-qualified firms only. The procurement covers essential antiviral and supportive medications required for comprehensive hepatitis treatment programs at multiple clinics across the province, reflecting PKLI's commitment to accessible liver disease management across its network of filter clinics serving diverse populations.
For Bidders: Our Analysis PAKISTANTENDER INSIGHT
Independent analysis by PakistanTender — not part of the official notice. Always confirm details against the original tender document.
Restricted tender for hepatitis medicines across 18 PKLI clinics statewide. Pre-qualification requirement significantly narrows the field—only firms already vetted by PKLI may bid. Multi-clinic distribution suggests consistent, recurring demand. Bidders must hold DRAP product registrations and pharmacy credentials. Timeline extends to August 2026, allowing moderate lead time for supply chain setup. Scale appears medium based on clinic count; exact quantities and budget not disclosed in this excerpt.
Who can bid: Only pre-qualified firms approved by PKLI are eligible. Bidders must typically hold valid NTN and SECP registration, DRAP product registration for supplied medicines, and valid pharmaceutical distribution licenses. Joint ventures permitted under outlined conditions. No black-listing or financial distress within preceding period.